$-0.08
(Market cap
$525 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
11.9
-
Debt to Equity
0.1
-
Book Value
$--
-
EPS
$-0.9
-
Face value
--
-
Shares outstanding
194,474,154
10 Years Aggregate
CFO
$-100.65 Mln
EBITDA
$-595.71 Mln
Net Profit
$-244.03 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Altimmune (ALT)
| -20.5 | -1.0 | -11.4 | -60.1 | -9.8 | -29.3 | -42.4 |
|
BSE Sensex
| -8.9 | 2.2 | 4.1 | -6.0 | 7.0 | 7.9 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Altimmune (ALT)
| -49.9 | -35.7 | -31.6 | 79.6 | -18.8 | 496.8 | -8.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Altimmune (ALT)
|
2.9 | 525.1 | 0.0 | -91.1 | -245,494.4 | -38.8 | -- | 1.8 |
| 293.2 | 37,128.5 | 4,286.9 | 577.2 | 20.3 | 88.2 | 69.9 | 34.5 | |
| 261.6 | 15,136.9 | 867.5 | 506.6 | -0.6 | -- | 26.3 | 26.7 | |
| 53.2 | 13,047.8 | 2,375.5 | 833.4 | 41.5 | 40.7 | 17.2 | 6.7 | |
| 186.4 | 28,000.8 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 20.9 | 4.5 | |
| 513.8 | 11,660.4 | 1,132.5 | -309.4 | -25.0 | -52.9 | -- | 21.4 | |
| 520.0 | 13,143.2 | 2,678.3 | 460.4 | 21.3 | 103.2 | 29 | 22.0 | |
| 620.1 | 63,945.5 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 14.9 | 2.0 | |
| 543.4 | 22,776.5 | 3,169.8 | 1,287.4 | 51.3 | 20.6 | 19.8 | 3.9 | |
| 480.2 | 114,626.1 | 12,255.1 | 4,338.3 | 42.2 | 23.7 | 26.8 | 5.9 |
Shareholding Pattern
View DetailsAbout Altimmune (ALT)
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial... for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland. Read more
-
President, CEO & Director
Dr. Vipin K. Garg Ph.D.
-
President, CEO & Director
Dr. Vipin K. Garg Ph.D.
-
Headquarters
Gaithersburg, MD
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Altimmune (ALT)
What is the current share price of Altimmune Inc (ALT) Today?
The share price of Altimmune Inc (ALT) is $2.87 (NASDAQ) as of 25-Jun-2026 16:21 EDT. Altimmune Inc (ALT) has given a return of -9.79% in the last 3 years.
What is the current PB & PE ratio of Altimmune Inc (ALT)?
Since, TTM earnings of Altimmune Inc (ALT) is negative, P/E ratio is not available.
The P/B ratio of Altimmune Inc (ALT) is 1.85 times as on 18-Jun-2026, a 57 discount to its peers’ median range of 4.30 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-4.12
|
1.62
|
|
2024
|
-5.40
|
4.16
|
|
2023
|
-7.43
|
3.39
|
|
2022
|
-9.71
|
4.44
|
|
2021
|
-3.93
|
1.92
|
What is the 52 Week High and Low of Altimmune Inc (ALT)?
The 52-week high and low of Altimmune Inc (ALT) are Rs 7.73 and Rs 2.56 as of 26-Jun-2026.
What is the market cap of Altimmune Inc (ALT)?
Altimmune Inc (ALT) has a market capitalisation of $ 525 Mln as on 18-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Altimmune Inc (ALT)?
Before investing in Altimmune Inc (ALT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.